When comparing clinical outcomes on CD19/CD22 Loop Bi-CAR T-cell therapy with different locations of CD19 scFv and CD22 scFv on CAR in NHL subjects, the PFS in the trial on CAR T cells expressing Bi-CAR with CD19 scFv distal to 4-1BB [31] was longer than the one with CD22 scFv distal to 4-1BB [34], both of which have similar OS. The gene discussed is CD22; the disease is non-Hodgkin lymphoma.